US-based pharmaceutical company Calyptus Pharmaceuticals, Inc. announced on Wednesday that the US Food and Drug Administration granted approval to an Abbreviated New Drug Application (ANDA) for a generic version of Brovana (Arformoterol Tartrate inhalation solution, EQ 0.015mg Base/2ml) to Calyptus' partner - VistaPharm, Inc.
Arformoterol Tartrate inhalation solution, EQ 0.015mg Base/2ml has been co-developed in collaboration with VistaPharm.
The product is intended for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, which includes chronic bronchitis and emphysema. It is for use by nebulisation only.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling